Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study

Imaoka,Natsuko; Hiratsuka,Masaharu; Osaki,Mitsuhiko; Kamitani,Hideki; Kambe,Atsushi; Fukuoka,Junya; Kurimoto,Masanori; Nagai,Shoichi; Okada,Futoshi; Watanabe,Takashi; Ohama,Eisaku; Kato,Shinsuke; Oshimura,Mitsuo

doi:10.3892/or.2012.1872

Prognostic significance of sirtuin 2 protein nuclear localization in glioma: An immunohistochemical study

Authors:
- Natsuko Imaoka
- Masaharu Hiratsuka
- Mitsuhiko Osaki
- Hideki Kamitani
- Atsushi Kambe
- Junya Fukuoka
- Masanori Kurimoto
- Shoichi Nagai
- Futoshi Okada
- Takashi Watanabe
- Eisaku Ohama
- Shinsuke Kato
- Mitsuo Oshimura
View Affiliations

Affiliations: Department of Biomedical Science, Institute of Regenerative Medicine and Biofunction, Graduate School of Medical Science, Tottori University, Yonago, Tottori 683-8503, Japan, Division of Molecular and Cell Genetics, School of Life Science, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan, Division of Neurosurgery, Department of Brain and Neurosciences,Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan, Department of Surgical Pathology, Toyama University Hospital, University of Toyama, Sugitani, Toyama 930-0194, Japan, Department of Neurosurgery, Faculty of Medicine, University of Toyama, Sugitani, Toyama 930-0194, Japan, Division of Pathological Biochemistry, School of Life Science, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan, Division of Neuropathology, Department of Brain and Neurosciences, Tottori University Faculty of Medicine, Yonago, Tottori 683-8503, Japan
Published online on: June 19, 2012 https://doi.org/10.3892/or.2012.1872
Pages: 923-930

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The sirtuin 2 (SIRT2) protein is a member of the sirtuin family and homologous to Sir2 (silent information regulator 2) of Saccharomyces cerevisiae. To assess the pathobiological significance of SIRT2 protein expression and/or subcellular localization in human glioma, we examined SIRT2 protein expression in human gliomas using a polyclonal anti-SIRT2 antibody and immunohistochemistry. In this study, samples from 23 patients with glioblastoma (GB, grade IV), 8 patients with diffuse astrocytoma (DA, grade II) and 5 healthy individuals were examined. We established a SIRT2 labeling index (SIRT2-LI) that represents the percentage of cells with SIRT2 localized to the nucleus. The mean SIRT2-LI was 65.8±18.6 in GB samples, 41.2±22.8 in DA samples, and 28.6±12.3 in normal control samples. The SIRT2-LI of GB samples was significantly higher than that of normal control samples (P<0.01, Mann-Whitney's U-test) and that of DA samples (P<0.05). Moreover, the SIRT2-LI was positively correlated with malignant progression. Specifically, samples from patients with GB were divided into two groups, low SIRT2-LI (<60%) and high SIRT2-LI (≥60%), and the patients with low SIRT2-LI samples survived significantly longer than patients with high SIRT2-LI samples (P<0.05, Kaplan-Meier method and log-rank test). In conclusion, SIRT2-LI was indicative of glioma malignancy, and it may be predictive of GB patient survival.

View Figures

View References

1	Huse JT and Holland EC: Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 10:319–331. 2010. View Article : Google Scholar : PubMed/NCBI
2	Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:1383–1387. 2000.PubMed/NCBI
3	Shete S, Hosking FJ, Robertson LB, et al: Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 41:899–904. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wrensch M, Jenkins RB, Chang JS, et al: Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 41:905–908. 2009. View Article : Google Scholar : PubMed/NCBI
5	Di Rocco F, Carroll RS, Zhang J and Black PM: Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery. 42:341–346. 1998.PubMed/NCBI
6	Xiao A, Wu H, Pandolfi PP, Louis DN and Van Dyke T: Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell. 1:157–168. 2002. View Article : Google Scholar : PubMed/NCBI
7	Ohgaki H and Kleihues P: Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453. 2007. View Article : Google Scholar : PubMed/NCBI
8	Hiratsuka M, Inoue T, Toda T, et al: Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. Biochem Biophys Res Commun. 309:558–566. 2003. View Article : Google Scholar : PubMed/NCBI
9	Michan S and Sinclair D: Sirtuins in mammals: insights into their biological function. Biochem J. 404:1–13. 2007. View Article : Google Scholar : PubMed/NCBI
10	North BJ and Verdin E: Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One. 2:e7842007. View Article : Google Scholar : PubMed/NCBI
11	Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004. View Article : Google Scholar : PubMed/NCBI
12	Pandithage R, Lilischkis R, Harting K, et al: The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol. 180:915–929. 2008. View Article : Google Scholar : PubMed/NCBI
13	Harting K and Knoll B: SIRT2-mediated protein deacetylation: An emerging key regulator in brain physiology and pathology. Eur J Cell Biol. 89:262–269. 2010. View Article : Google Scholar : PubMed/NCBI
14	Inoue T, Nakayama Y, Yamada H, et al: SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle. 8:1279–1291. 2009. View Article : Google Scholar : PubMed/NCBI
15	Inoue T, Hiratsuka M, Osaki M and Oshimura M: The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle. 6:1011–1018. 2007. View Article : Google Scholar : PubMed/NCBI
16	Inoue T, Hiratsuka M, Osaki M, et al: SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene. 26:945–957. 2007. View Article : Google Scholar : PubMed/NCBI
17	Kato M, Brijlall D, Adler SA, Kato S and Herz F: Effect of hyperosmolarity on alkaline phosphatase and stress-response protein 27 of MCF-7 breast cancer cells. Breast Cancer Res Treat. 23:241–249. 1992. View Article : Google Scholar : PubMed/NCBI
18	Louis DN, Ohgaki H, Wiestler OD, et al: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
19	Fukuoka J, Fujii T, Shih JH, et al: Chromatin remodeling factors and BRM/BRG1 expression as prognostic indicators in non-small cell lung cancer. Clin Cancer Res. 10:4314–4324. 2004. View Article : Google Scholar : PubMed/NCBI
20	Werner HB, Kuhlmann K, Shen S, et al: Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J Neurosci. 27:7717–7730. 2007. View Article : Google Scholar : PubMed/NCBI
21	Holland EC: Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet. 2:120–129. 2001. View Article : Google Scholar : PubMed/NCBI
22	Zhu Y, Guignard F, Zhao D, et al: Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 8:119–130. 2005. View Article : Google Scholar : PubMed/NCBI
23	Nahhas F, Dryden SC, Abrams J and Tainsky MA: Mutations in SIRT2 deacetylase which regulate enzymatic activity but not its interaction with HDAC6 and tubulin. Mol Cell Biochem. 303:221–230. 2007. View Article : Google Scholar : PubMed/NCBI
24	Lee YS, Lim KH, Guo X, et al: The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 68:7561–7569. 2008. View Article : Google Scholar : PubMed/NCBI
25	Schiffer D, Cavalla P, Chio A, Richiardi P and Giordana MT: Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol. 34:31–35. 1997. View Article : Google Scholar : PubMed/NCBI
26	Di X, Nishizaki T, Harada K, Kajiwara K, Nakayama H and Ito H: Proliferative potentials of glioma cells and vascular components determined with monoclonal antibody MIB-1. J Exp Clin Cancer Res. 16:389–394. 1997.
27	Uematsu M, Ohsawa I, Aokage T, et al: Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol. 72:231–238. 2005. View Article : Google Scholar : PubMed/NCBI
28	Johannessen AL and Torp SH: The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas. Pathol Oncol Res. 12:143–147. 2006. View Article : Google Scholar : PubMed/NCBI
29	Moskowitz SI, Jin T and Prayson RA: Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol. 76:193–200. 2006. View Article : Google Scholar : PubMed/NCBI
30	Rushing EJ, Sandberg GD and Horkayne-Szakaly I: High-grade astrocytomas show increased Nestin and Wilms' tumor gene (WT1) protein expression. Int J Surg Pathol. 18:255–259. 2010. View Article : Google Scholar : PubMed/NCBI
31	Ducray F, Idbaih A, Wang XW, Cheneau C, Labussiere M and Sanson M: Predictive and prognostic factors for gliomas. Expert Rev Anticancer Ther. 11:781–789. 2011. View Article : Google Scholar : PubMed/NCBI